Condition

Diabetes Mellitus, Type II

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 62 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials62
Recruiting1
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

60 shown
The EMPA-FIT StudyNCT06846411 · 2024-01-01
RECRUITING
Evaluation of the Effect of Nurse Coaching Program on Self-management and Skin Care Behaviors in Patients With DiabetesNCT06717256 · 2024-12-20
NOT_YET_RECRUITING
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes MellitusNCT06498284 · 2024-04-25
COMPLETED
Differences in Postprandial Glucose ChangesNCT05957224 · 2023-11-15
UNKNOWN
Development and Exploration of the Effectiveness and Feasbility of a Digital Intervention for Type 2 Diabetes MellitusNCT05364476 · 2022-04-11
COMPLETED
TARDIS - Photo Elicitation and InterventionNCT06972251 · 2022-03-08
COMPLETED
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin MonotherapyNCT04667143 · 2021-01-01
UNKNOWN
´Sit Less, Move More' at Work: mHealth Intervention on Office Employees With Diabetes Type 2.NCT04092738 · 2019-03-04
UNKNOWN
Fenofibrate in Type 2 DiabetesNCT03829514 · 2019-02-04
COMPLETED
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes MellitusNCT03596177 · 2018-09-26
COMPLETED
Insulin Sensitivity During Hyperbaric Oxygen Compared to Hyperbaric AirNCT03138746 · 2018-08-13
COMPLETED
Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308NCT03616392 · 2018-07-25
COMPLETED
GOLO Open-Label Pilot 1NCT03478202 · 2017-08-01
COMPLETED
Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 DiabetesNCT03014011 · 2017-06-13
COMPLETED
Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular EdemaNCT02985242 · 2017-06-12
TERMINATED
Episodic to Real-Time Care in Diabetes Self-ManagementNCT03012074 · 2017-03-02
COMPLETED
Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 DiabetesNCT02946632 · 2016-12-01
UNKNOWN
Measuring Patient Engagement in Diabetes CareNCT02988427 · 2016-12-01
WITHDRAWN
Impact of Periodontal Therapy on Patients With DiabetesNCT04830969 · 2016-11-08
COMPLETED
Evaluate the Drug-drugs Interaction Between Lobeglitazone and EmpagliflozinNCT02854748 · 2016-08-01
UNKNOWN
CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)NCT02824874 · 2016-04-01
COMPLETED
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male VolunteersNCT02685774 · 2016-02-01
COMPLETED
Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes MellitusNCT03112382 · 2015-11-01
COMPLETED
Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male VolunteersNCT02648854 · 2015-10-01
COMPLETED
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male VolunteersNCT02627027 · 2015-08-01
COMPLETED
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male VolunteersNCT02565368 · 2015-07-01
COMPLETED
Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and BloodNCT02650206 · 2015-01-01
COMPLETED
Impact of Sleep and Meal Timing on Food Intake RegulationNCT02347020 · 2014-10-01
COMPLETED
Tablet-Aided BehavioraL Intervention EffecT on Self-management SkillsNCT02128854 · 2014-08-14
COMPLETED
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes MellitusNCT02175121 · 2014-08-01
COMPLETED
Microclinic Social Induction Pilot Intervention for Diabetes and Obesity Management in QatarNCT02175537 · 2014-06-01
COMPLETED
Detection of Diffuse Scar in Patients With DiabetesNCT01794091 · 2013-08-01
WITHDRAWN
Technology Intensified Diabetes Education Study in African AmericansNCT02088658 · 2013-05-01
COMPLETED
Bioequivalence Study for Acarbose / Metformin FDCNCT01728740 · 2012-09-01
COMPLETED
Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II DiabeticsNCT01654120 · 2011-12-01
COMPLETED
Micro-Clinic Obesity and Metabolic Risk Prevention ProgramNCT01651065 · 2011-06-01
COMPLETED
A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.NCT01301092 · 2011-02-01
COMPLETED
Single Dose Escalation Study of PF-05190457 in Healthy VolunteersNCT01247896 · 2010-12-01
COMPLETED
The Effects of a Regenerative Mitochondrial Medication on Physiological Parameters in Case of Diabetes Mellitus Type IINCT01197092 · 2010-11-01
UNKNOWN
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes MellitusNCT01194258 · 2010-08-01
COMPLETED
Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure ControlNCT01066039 · 2010-04-01
COMPLETED
Mechanisms of Glycemic Improvement After Gastrointestinal SurgeryNCT01025999 · 2010-01-01
COMPLETED
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With PioglitazoneNCT00970424 · 2009-08-01
TERMINATED
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without MetforminNCT00947557 · 2009-07-01
TERMINATED
Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic PatientsNCT00649909 · 2008-11-01
COMPLETED
Telephone Delivered Behavioral Skills Intervention for Blacks With T2DMNCT00929838 · 2008-08-01
COMPLETED
Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-RespondersNCT00660790 · 2008-04-01
COMPLETED
Jordan Diabetes Microclinic ProjectNCT01596244 · 2008-04-01
COMPLETED
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 DiabetesNCT00642278 · 2008-04-01
COMPLETED
Diabetes Mellitus Type II and Tissue OxygenationNCT00554697 · 2007-11-01
TERMINATED
Study of INT-747 in Patients With Diabetes and Presumed NAFLDNCT00501592 · 2007-07-01
COMPLETED
Comparison of Apidra to Regular Insulin in Hospitalized PatientsNCT00528918 · 2007-06-01
COMPLETED
Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic NephropathyNCT00237952 · 2005-08-01
COMPLETED
The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM)NCT00131287 · 2005-07-01
COMPLETED
Rosiglitazone to Reverse Metabolic Defects in DiabetesNCT00094796 · 2004-10-20
COMPLETED
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)NCT00086515 · 2004-06-30
COMPLETED
Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)NCT00081328 · 2004-05-01
COMPLETED
A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes MellitusNCT00952445 · 2003-12-01
COMPLETED
Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DMNCT00577590 · 2003-10-01
COMPLETED
Dyslipidemia in Type 2 Diabetes (0767-034)NCT00547274 · 2003-07-01
TERMINATED

Common interventions

PlaceboDRUG9MetforminDRUG5DutogliptinDRUG2RosiglitazoneDRUG216 weeks digital interventionBEHAVIORAL1Acarbose (Glucobay, BAYG5421)DRUG1Acarbose/Metformin FDC (BAY81-9783)DRUG1BisoprololDRUG1Brachial artery reactivity testingPROCEDURE1Canagliflozin (JNJ-28431754)DRUG1Chlorhexidine gluconate oral rinseDRUG1CKD-395 0.25/500mgDRUG1CKD-395 0.25/750mgDRUG1CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1TDRUG1CKD-395 0.5/1000mgDRUG1Combined InterventionBEHAVIORAL1Comparator: placebo (unspecified) / Duration of Treatment: 21 WeeksDRUG1ControlBEHAVIORAL1D308, CKD-501DRUG1Diabetes Knowledge/InformationBEHAVIORAL1Duvie Tab. 0.5mgDRUG1Duvie Tab. 0.5mg + Januvia Tab. 100mgDRUG1Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mgDRUG1Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mgDRUG1Duvie Tab. 0.5mg, Glucophage XR Tab. 500mgDRUG1

Trial status mix

COMPLETED47
UNKNOWN6
TERMINATED5
WITHDRAWN2
NOT_YET_RECRUITING1
RECRUITING1

Phase mix

NA18
PHASE112
PHASE211
PHASE39
PHASE47
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.